 Adamas Pharmaceuticals recently reported its Q3 earnings with a slight beat on EPS and a slight miss on revenue. The company did report record product sales for GOCOVRI. Adamas looks to have found a rhythm for GOCOVRI and the commericial numbers continue to improve. In addition,i t is now collecting royalties for NAMZARIC. 